More 
• Cover Story - Triglyceride Trouble from Tumors - A team led by South Florida researchers has found that cancer cells alter both the amount and the type of lipids in dendritic cells, decreasing their ability to initiate immunity. The findings suggest that it may be possible to improve the poor immune response seen in many cancer patients.
More
• Targets & Mechanisms - Inhibiting E3 Ligases - Two groups of researchers have identified inhibitors of E3 ubiquitin ligase, which has been considered difficult, if not impossible, to target with small molecules. The findings could lead to compounds that are more specific disrupters of tumor cell proliferation than the proteasome inhibitor Velcade bortezomib.
More
• Targets & Mechanisms - Son of Dimebon - University of Texas Southwestern researchers have identified a small molecule similar to Medivations Dimebon that is better at stimulating neurogenesis and provides some hints about mechanism of action. However, its target needs to be identified.
More
• Targets & Mechanisms - Attacking Cancers Secretive Side - Researchers at the Weizmann Institute of Science have shown that antibodies targeting tumor-specific EGFR ligands could boost the effectiveness of standard chemotherapies to treat pancreatic and other cancers.
More
• The Distillery - This Week in Therapeutics - Treating multiple sclerosis by blocking CXCR2 to promote remyelination; using CTR1 inhibitors to prevent hearing loss associated with cisplatin chemotherapy; treating neurodegenerative diseases with the HDAC inhibitor Tubastatin A; and more
More
• The Distillery - This Week in Techniques - Pressure-driven delivery of GDNF via adenoviral vector to help treat PD; double chemical cross-links to improve pharmacological properties of large peptide inhibitors; rapid, noninvasive, image-based classification of tumor stage to help guide brain tumor treatment; and more
More
• To download a Free Issue - click here